medigraphic.com
ISSN 1560-4381 (Print)

2017, Number 1

<< Back Next >>

Correo Científico Médico 2017; 21 (1)

Beyond the definition of metabolic syndrome: uric acid, high sensitivity c reactive protein and global cardiovascular risk

Vega AJ, Guimara MMR, Vega AL

Language: English
References: 28
Page: 70-86
PDF size: 577.12 Kb.


ABSTRACT

Introduction: the metabolic syndrome is becoming one of the main problems in public health.
Objective: to evaluate the relation between metabolic syndrome and uric acid, high sensitivity c reactive protein, total cardiovascular risk and cardiovascular events.
Methods: a study of cases controls nested in a dynamic cohort was carried out in Velasco Teaching Polyclinic from 2010 to 2015, the cases were 67 patients that developed metabolic syndrome during the period and the control group were 67 patients matched by sex and age ± 5 years. The participants underwent a physical examination, anthropometry, laboratory test; all the study participants were under continuous surveillance during 4.5 years for development of cardiovascular events.
Results: the waist circumference (p = 0.000), systolic (p= 0.0042) and diastolic blood pressure (p= 0.0298), high sensitivity c reactive protein (p= 0.0039) and uric acid (p= 0.0283) were significantly associate in both groups. The body mass index was higher than 30 kg/m2 (OR 7.54; CI95%:3.35-16.9), LDL cholesterol greater than 4.16 mmol/l (OR 3.49; CI 95%:1.58-7.70) and hs CRP higher than 1 mg/dl (OR 3.59; CI 95%:1.51-8.51) showed statistically significant differences according to groups of studies. Global cardiovascular risk greater 20%, it was 3.84 times higher in the group with metabolic syndrome (CI 95%:1.67-8.82), 13.4% of the patients with metabolic syndrome developed a cardiovascular event during the period in comparison with the 2.9% in the group without metabolic syndrome (OR= 5.04; CI 95%: 1.04-24.3).
Conclusions: metabolic syndrome was significantly associated with mean level of uric acid, high sensitivity c reactive protein, total cardiovascular risk and cardiovascular events.


REFERENCES

  1. Zhou H, Guo Zr, Hu Xs , Yu Lg, Xu Bx , Wu M, et al. An exploratory analysis of dynamic change of metabolic syndrome in relation to the risk of developing cardiovascular disease in a chinese cohort. Iranian J Publ Health. 2012[cited 2013 Jan 14]; 41(4):26-34. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481612/pdf/ijph-41-26.pdf

  2. Zhu Z, Liu Y, Zhang C, Yuan Z, Zhang Q, Tang Fang, et al. Identification of cardiovascular risk components in urban chinese with metabolic syndrome and application to coronary heart disease prediction: A longitudinal study. PLoS ONE. 2013[cited 2014 Jul 10]; 8(12): 1-10. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866125/pdf/pone.0084204.pdf

  3. Zimmer P, George K, Alberti M, Serrano M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol. 2005[cited 6 Oct 2006]; 58(12):1371-1375. Available in: http://www.revespcardiol.org/es/content/articulo/13082533/

  4. Hutcheson R, Rocic P. The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: The great exploration. Exp Diabetes Res. 2012[cited 27 Jun 2013];2012(2012):1-13. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399393/

  5. Simmons RK, Alberti KG, Gale EA, .Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO expert Consultation . Diabetologia. 2010. [cited 14 Jan 2011];53(4):600–605. Available in: http://link.springer.com/article/10.1007/s00125-009-1620-4

  6. Pineda CA. Metabolic syndrome: definition, history, criterion. Colombia Med.2013[cited 14 Jan 2014];39(1):96-106.Available in: http://bibliotecadigital.univalle.edu.co/bitstream/10893/4753/1/Metabolic%20syndrome.pdf

  7. D’Agostino RB, Pencina MJ, Massaro, JM, Coady S. Cardiovascular disease risk assessment: Insights from Framingham. Glob Heart. 2013. [cited 2014 Oct 7]; 8(1): 11–23. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673738/

  8. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008 [cited 15 Feb 2013]; 117(6):743-753.Available in: http://circ.ahajournals.org/cgi/content/full/117/6/743

  9. Rohla M, Weiss TW. Adipose tissue, inflammation and atherosclerosis. Clin Lipidology. 2014[cited 30 Jun 2014]; 9(1):71-81.Available in: http://www.futuremedicine.com/doi/pdf/10.2217/clp.13.80

  10. Alegria Ezquerra E, Castellano Vázquez JM, Alegria Barrero A. Obesity, metabolic syndrome and diabetes: cardiovascular implications and therapy. Rev Esp Cardiol. 2008[cited 30 Mar 2012];61(7):752-764.Available in http://www.revespcardiol.org/es/obesity-metabolic-syndrome-and-diabetes/articulo/13123996/

  11. Lukich A, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: Relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol. 2014[cited 14 Dec 2014]; 13(141).Available in: http://www.medscape.com/viewarticle/835945_1

  12. Peng TC, Wang CC, Wei Kao T, Hsin Chan J, Yang YH, Wen ChangY, et al. Relationship between hyperuricemia and lipid profile in US adults. Biomed Research International.2015 [cited 2015 Jul 10 ]:1-7.Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299312/

  13. Abreu da Silva H, Cardoso JC, Bressan J, Miranda H. Relation between uric acid and metabolic syndrome in subjects with cardiometabolic risk. Einstein. 2015 [cited 2015 May 19]13(2): 202-208. Available in: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082015005053194&lng=en&nrm=iso&tlng=en

  14. Lee JK , Ryoo JH , Choi JM , Park SK. Serum uric acid level and the incidence of metabolic syndrome in middle-aged Korean men: A 5-year follow up study. J Prev Med Public Health 2014 [cited 2015 Jan 14];47:317-326. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263007/

  15. Li LX, Dong XH, Li MF, Zhan R, Li TT, ShenJ,et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. Journal of Hypertension 2015 [cited 2015 Jul 10]; 33(3): 482-490. Available in:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309490/

  16. Grimaldi-Bensouda L, Alperovitch A, Aubrum E, Danchin N, Rossigni M, Abenhaim L, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015.[cited 2015 Jul 10]; 74(5): 836-842. Available in: http://www.medscape.com/viewarticle/844859?src=wnl_edit_tpal

  17. Miguel-Soca P. Predictores de riesgo cardiometabolico. Revista Finlay. 2015 [cited 2015 Jul 3]; 5(2):80-82. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/357

  18. Mottillo F. Filion K, Genest J, Joseph J,Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis.JACC.2010 [cited 2011 Jun 27]; 56(14):1113-32.Available in: http://www.sciencedirect.com/science/article/pii/S0735109710026380

  19. Ridker PM, Buring JE, Cook N, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events An 8-year follow-up of 14 719 initially healthy american women. Circulation. 2003[cited 2005 Sep 19]; 107:391-397.Available in: http://circ.ahajournals.org/content/107/3/391.full.pdf+html

  20. The Emerging Risk Factors Collaboration. C - reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012[cited 2013 Jan 14]; 367(14): 1310–1320. Available in: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714101/pdf/nihms488711.pdf

  21. Vega J, Guimara M, Garces Y, Garcia Y, Vega L. Proteina C reactiva de alta sensibilidad y riesgo de enfermedad cardiovascular. CCM. 2015[cited 2015 Jul 10]; 19(2):190-201. Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/978/621

  22. Charakida M, Masi S, Deanfield JE. The Year in Cardiology 2012: focus on cardiovascular disease prevention. Eur Heart J. 2013 [cited 2014 Nov 21]; 34: 314–7. Available in http://eurheartj.oxfordjournals.org/content/ehj/early/2013/01/02/eurheartj.ehs429.full.pdf

  23. Nordet P, Mendis M, Dueñas A, de la Noval R, Armas N. Total cardiovascular risk assessment and management using two prediction tools, with and without blood cholesterol. MEDICC Review.2013 [cited 2014 Nov 26]; 15(4). Available in: http://www.scielosp.org/scielo.php?pid=S1555-79602013000400009&script=sci_arttext

  24. Aljutaili M, Becker C, Witt S, Holle R, Leidl L. Should health insurers target prevention of cardiovascular disease?: A cost-effectiveness analysis of an individualized programme in Germany based on routine data. BMC Health Services Research.2014 [cited 2014 Nov 26]; 14:263.Available in: http://www.biomedcentral.com/1472-6963/14/263

  25. Vega J, Guimará M, Vega L. Riesgo cardiovascular, una herramienta útil para la prevención de las enfermedades cardiovasculares. Rev Cubana Med Gen Integr.2011 [cited 2013 Dec 12]; 27(1):91-97. Available in: http://scielo.sld.cu/pdf/mgi/v27n1/mgi10111.pdf

  26. Vega J, Guimara M, Garces Y, Vega L, Rivas M. Predicción del riesgo coronario y cardiovascular global en atención primaria de salud. CCM. 2015 [cited 2015 Nov 27] 19(2):202-211. Available in: http://www.revcocmed.sld.cu/index.php/cocmed/article/download/979/622

  27. Tarragó E, Miguel Soca PE, Cruz L, Santiesteban Y. Factores de riesgo y prevención de la enfermedad isquémica. CCM. 2012 [cited 2014 Nov 20]; 16(2). Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/505

  28. Rivas Vázquez D, Miguel Soca PE, Llorente Columbié Y, Marrero Ramírez GM. Comportamiento clínico y epidemiológico del síndrome metabólico en adultos. Rev Cubana Med Gen Integr. 2015 [citado 2016 Mar 09]; 31(3). Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252015000300001&lng=es




2020     |     www.medigraphic.com